• 

  April 8, 2026

  Cellbricks Therapeutics Raises €10M to Advance Biofabricated Tissue Implants for Wound Care and Reconstructive Surgery

  Ricky Solorzano

• 

  April 6, 2026

  NAMs, New Approach Methodologies for Drug Discovery: What It Means for the Future of Alternatives to Animal Testing and Biofabrication

  Ricky Solorzano

• 

  April 5, 2026

  Canada Just Bet Another $280M on Bioprinted Medicines, Here’s What It Means for the Industry

  Ricky Solorzano

• 

  March 8, 2026

  UC San Diego’s ARPA-H Project Targets the A Different Approach for the Bioprinted LIVER Program

  Ricky Solorzano

• 

  March 6, 2026

  Japan Moves Toward First Commercial iPS Cell Therapies

  Ricky Solorzano

• 

  March 3, 2026

  Cellares Raises $257M to Industrialize Cell Therapy Manufacturing

  Ricky Solorzano

• 

  February 26, 2026

  UT Southwestern VITAL Program Wins ARPA-H Award to Bioprint Personalized, Immune-Compatible Livers

  Ricky Solorzano

• 

  February 20, 2026

  United Therapeutics Reports Breakthrough Phase 1 Results for Bioengineered Liver Support System

  Ricky Solorzano

• 

  February 16, 2026

  Aspect Biosystems and Novo Nordisk Deepen Partnership to Advance Curative Diabetes Therapies

  Ricky Solorzano

• 

  February 13, 2026

  WFIRM Secures ARPA-H Award to Advance On-Demand Bioprinted Kidneys

  Ricky Solorzano